ATE306931T1 - Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer - Google Patents

Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Info

Publication number: ATE306931T1
Authority: AT; Austria
Prior art keywords: beta; alzheimer; amyloid; suppression; changes associated
Prior art date: 1997-12-03

Application number

AT98961894T

Other languages

English (en)

Inventor

Howard L Weiner

Dennis J Selkoe

Original Assignee

Neuralab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-03

Filing date

1998-12-03

Publication date

2005-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306931(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-12-03 Application filed by Neuralab Ltd filed Critical Neuralab Ltd

2005-11-15 Application granted granted Critical

2005-11-15 Publication of ATE306931T1 publication Critical patent/ATE306931T1/de

Links

102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
230000001629 suppression Effects 0.000 title 1
239000002552 dosage form Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Marine Sciences & Fisheries (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Engine Equipment That Uses Special Cycles (AREA)

AT98961894T 1997-12-03 1998-12-03 Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer ATE306931T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US6721997P	1997-12-03	1997-12-03
US7969798P	1998-03-27	1998-03-27
PCT/US1998/025694 WO1999027949A1 (en)	1997-12-03	1998-12-03	METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE

Publications (1)

Publication Number	Publication Date
ATE306931T1 true ATE306931T1 (de)	2005-11-15

Family

ID=26747618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98961894T ATE306931T1 (de)	1997-12-03	1998-12-03	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Country Status (8)

Country	Link
EP (1)	EP1033998B1 (de)
JP (2)	JP2002511385A (de)
AT (1)	ATE306931T1 (de)
AU (1)	AU742970C (de)
CA (1)	CA2312475C (de)
DE (2)	DE69831971T2 (de)
ES (1)	ES2253839T3 (de)
WO (1)	WO1999027949A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0866805A1 (de)	1995-12-12	1998-09-30	Karolinska Innovations AB	Peptide, das die KLVFF Sequenz von beta-Amyloid bindet
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
EP1033998B1 (de) *	1997-12-03	2005-10-19	Neuralab, Ltd.	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
NZ521939A (en)	2000-05-22	2004-04-30	Univ New York	Inducing an immune response to amyloid beta peptides and amyloid deposits using a synthetic non-amylogenic but immunogenic peptide
EP2082749A3 (de)	2000-07-07	2010-06-30	Bioarctic Neuroscience AB	Vorbeugung und Behandlung für Morbus Alzheimer
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7320793B2 (en)	2001-01-19	2008-01-22	Cytos Biotechnology Ag	Molecular antigen array
CA2466841A1 (en)	2001-11-21	2003-06-05	New York University	Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
DE60336902D1 (de)	2002-07-19	2011-06-09	Cytos Biotechnology Ag	Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
US20070010435A1 (en)	2002-12-19	2007-01-11	New York University	Method for treating amyloid disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
GB0424563D0 (en)	2004-11-05	2004-12-08	Novartis Ag	Organic compounds
ES2396555T3 (es)	2004-12-15	2013-02-22	Janssen Alzheimer Immunotherapy	Anticuerpos que reconocen péptido beta amiloide
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
PT1976877E (pt)	2005-11-30	2014-04-29	Abbvie Inc	Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt)	2005-11-30	2011-09-20	Abbott Lab	anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
BRPI0709050B1 (pt)	2006-03-23	2018-12-26	Bioarctic Neuroscience Ab	anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Verfahren zur behandlung von amyloidosen
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
EP2558494B1 (de)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta-bindende proteine
CN105348387B (zh)	2010-08-14	2020-08-25	Abbvie 公司	β淀粉样蛋白结合蛋白
WO2013013056A1 (en)	2011-07-19	2013-01-24	New York University	Method for treating amyloid disease
US9926353B2 (en)	2011-07-19	2018-03-27	New York University	Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US20150290158A1 (en) *	2012-11-09	2015-10-15	Elliott C. Lasser	X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of cns inflammation and inflammation associated conditions
HRP20210680T1 (hr)	2014-07-10	2021-06-11	Bioarctic Ab	POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223482A (en) *	1986-11-17	1993-06-29	Scios Nova Inc.	Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
JP2980677B2 (ja) *	1990-04-27	1999-11-22	マクマイケル，ジョン	不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
ATE202940T1 (de) *	1994-05-25	2001-07-15	John Mcmichael	Mittel und methoden zur behandlung von plaque- krankheiten
AU6113896A (en) *	1995-06-05	1996-12-24	Brigham And Women's Hospital	Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
WO1997018855A1 (en) *	1995-11-21	1997-05-29	Eduard Naumovich Lerner	Device for enhanced delivery of biologically active substances and compounds in an organism
ZA97452B (en) *	1996-01-25	1997-08-15	Trinity College Dublin	Streptococcus equi vaccine.
JPH09208485A (ja) *	1996-01-31	1997-08-12	Teijin Ltd	ペプチド・蛋白質性薬物の水難溶性組成物
EP1033998B1 (de) *	1997-12-03	2005-10-19	Neuralab, Ltd.	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

1998
- 1998-12-03 EP EP98961894A patent/EP1033998B1/de not_active Expired - Lifetime
- 1998-12-03 DE DE69831971T patent/DE69831971T2/de not_active Expired - Lifetime
- 1998-12-03 CA CA2312475A patent/CA2312475C/en not_active Expired - Lifetime
- 1998-12-03 DE DE1033998T patent/DE1033998T1/de active Pending
- 1998-12-03 AT AT98961894T patent/ATE306931T1/de not_active IP Right Cessation
- 1998-12-03 ES ES98961894T patent/ES2253839T3/es not_active Expired - Lifetime
- 1998-12-03 WO PCT/US1998/025694 patent/WO1999027949A1/en not_active Ceased
- 1998-12-03 AU AU17099/99A patent/AU742970C/en not_active Expired
- 1998-12-03 JP JP2000522934A patent/JP2002511385A/ja active Pending
2010
- 2010-04-02 JP JP2010086400A patent/JP2010215627A/ja active Pending

Also Published As

Publication number	Publication date
AU742970C (en)	2003-03-20
EP1033998A4 (de)	2003-06-04
AU742970B2 (en)	2002-01-17
JP2010215627A (ja)	2010-09-30
WO1999027949A1 (en)	1999-06-10
DE69831971D1 (de)	2006-03-02
EP1033998A1 (de)	2000-09-13
ES2253839T3 (es)	2006-06-01
AU1709999A (en)	1999-06-16
CA2312475C (en)	2010-08-03
EP1033998B1 (de)	2005-10-19
JP2002511385A (ja)	2002-04-16
WO1999027949A9 (en)	1999-09-10
DE1033998T1 (de)	2001-05-23
CA2312475A1 (en)	1999-06-10
DE69831971T2 (de)	2006-07-06

Legal Events

Date	Code	Title	Description
2006-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69831971D1 (de)	2006-03-02	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
EP0552256A4 (de)	1994-04-27
GEP20053715B (en)	2005-12-26	Prevention and Treatment of Amyloidogenic Disease
DE69331409D1 (de)	2002-02-07	Oral 1alpha-hydroxyprevitamin d
YU59092A (sh)	1994-12-28	Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
SE9703191D0 (sv)	1997-09-04	Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
ATE338771T1 (de)	2006-09-15	Antagonisten des intestinotrophen glp-2 peptides
WO1994027589A3 (en)	1995-01-26	Antidepressant dosage form
EP1024827A4 (de)	2002-08-28	Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen
ATE234602T1 (de)	2003-04-15	Verabreichungsform zur abgabe von steigenden wirkstoffdosen
DE3875108D1 (de)	1992-11-05	Physiologisch aktives polypeptid und pharmazeutische komposition.
RU94046091A (ru)	1996-09-27	Полипептидные антагонисты бомбезина, фармацевтическая композиция и способ лечения
IT1222395B (it)	1990-09-05	Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
GR1000419B (el)	1992-06-30	Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
NO943288L (no)	1995-03-22	Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
FR2768341B1 (fr)	2000-04-14	Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
TR200000455T2 (tr)	2000-09-21	Alzheimer hastalığının tedavisinde fankinonun kullanılması.
MX9707642A (es)	1997-12-31	Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
PT1150703E (pt)	2006-05-31	Terapia de esclerose multipla com chaperonina 10 e beta-interferao
BG103905A (en)	2000-07-31	New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69314586D1 (de)	1997-11-20	Arzneimittelzusammensetzung enthaltend TCF-II
MY112888A (en)	2001-10-31	Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
EP0579765A4 (en)	1994-08-24	Method and composition for the treatment of herpes related disorders
DE59410137D1 (de)	2002-07-18	Neue pharmazeutische zubereitungen zur oralen verabreichung enthaltend cyclosporin
DE69822234D1 (de)	2004-04-08	Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion